[{"indications": "Indications\u00a0 see under Dose below", "name": "DARBEPOETIN ALFA", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "9 Nutrition and blood", "9.1 Anaemias and some other blood disorders", "9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias", "Erythropoietins", "DARBEPOETIN ALFA"], "cautions": "Cautions\u00a0see Epoetin", "side-effects": "Side-effects\u00a0see Epoetin; also, oedema,\r\ninjection-site pain; isolated reports of pure red cell aplasia, particularly\r\nfollowing subcutaneous administration in patients with chronic renal\r\nfailure (discontinue therapy)\u2014see also notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/106108.htm", "doses": ["Symptomatic anaemia associated with chronic renal failure\r\nin patients on dialysis (see also MHRA/CHM advice), adult and child over\r\n11 years, by subcutaneous or intravenous injection, initially 450\u00a0nanograms/kg once weekly,\r\nadjusted according to response by approx. 25% at intervals of at least\r\n4 weeks; maintenance dose, given once weekly or once\r\nevery 2 weeks"], "pregnancy": "Pregnancy\u00a0no evidence of harm in animal studies\u2014manufacturer\r\nadvises caution "}]